SPARC Binding ScFvs Targeted Delivery via Peptide Coupling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies and diagnostic methods lack effective targeting and delivery mechanisms for therapeutic or diagnostic agents to disease sites, particularly in cancers where SPARC is overexpressed, limiting their therapeutic or diagnostic efficacy.
Innovation Solution
Development of pharmaceutical compositions coupling therapeutic or diagnostic agents with SPARC-binding-peptides (SBPs) and pharmaceutically acceptable carriers, including albumin-binding-peptides (ABPs), to specifically target SPARC-expressing sites, such as tumors, for enhanced delivery and action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic or diagnostic agents are administered systemically, then they can reach disease sites, but they lack effective targeting and delivery mechanisms resulting in limited therapeutic or diagnostic efficacy
Solution Approach 1:
The patent uses SPARC-binding peptides as intermediary molecules that specifically bind to SPARC protein overexpressed on tumor cells. This mediator approach enables targeted delivery of therapeutic or diagnostic agents to disease sites without requiring complex engineered delivery systems, thereby improving therapeutic efficacy while maintaining ease of manufacture
Solution Approach 2:
The patent modifies the physical-chemical parameters of therapeutic or diagnostic agents by coupling them to SPARC-binding peptides. This parameter change (adding a targeting moiety) transforms non-specific systemic agents into targeted delivery vehicles, improving reliability of therapeutic action without significantly complicating the manufacturing process
2Quantity of substance
If therapeutic agents are delivered without specific targeting, then administration is simple, but concentration and retention at disease sites are insufficient
Solution Approach 1:
The patent creates composite pharmaceutical compositions by coupling therapeutic or diagnostic agents with SPARC-binding peptides. This composite structure combines the targeting capability of the peptide with the therapeutic or diagnostic function of the agent, increasing concentration and retention at disease sites while maintaining relatively simple composition structure
Solution Approach 2:
The patent segments the pharmaceutical composition into distinct functional components: the SPARC-binding peptide portion that provides targeting and the therapeutic or diagnostic agent portion that provides the therapeutic or diagnostic effect. This segmentation allows each component to perform its specific function optimally, improving agent concentration at the disease site without excessive complexity
Data Source
AI summary
The invention provides compositions comprising SPARC binding ScFv and its use.